Business

Clarkson Capital Issues Price Target With 44.4% Upside On Atwood Oceanics

Clarkson Capital Issues Price Target With 44.4% Upside On Atwood Oceanics

Evercore ISI restated a "hold" rating and issued a $10.00 price target on shares of Atwood Oceanics in a research report on Tuesday, February 7th. With the last close down -19.38% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the same period.



Everything you need to know if Trump impeachment moves start

October 28, 2016: Days before the election, Comey informs Congress by letter that he is reopening the investigation into Clinton's email practices based on new evidence, citing the discovery of emails on a laptop used by a top Clinton aide.



(CMCSA) Rating Reiterated by Deutsche Bank AG

On the other hand Comcast Corporation (NASDAQ:CMCSA) has Relative Strength Index (RSI 14) of 52.63 along with Average True Range (ATR 14) of 0.60, where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement.



Oil rises 2% after Saudi and Russian Federation back longer supply cut

Russia's Energy Ministry plans no compensations to Russian companies due to a probable extension of the agreement on oil production cut, Minister Alexander Novak said Tuesday. Even so, McGillian said, "We still have a near record overhang and signs of increasing production in areas of the world outside the producers that agreed to the cuts".


Coherus BioSciences, Inc. (CHRS) Under Analyst Spotlight

Coherus BioSciences, Inc. (CHRS) Under Analyst Spotlight

Other research analysts have also issued research reports about the company. BMO Capital Markets reiterated an "outperform" rating and set a $54.00 price objective on shares of Coherus Biosciences in a research report on Monday. 01/20/2016 - Credit Suisse began new coverage on Coherus BioSciences , Inc. giving the company a "outperform" rating. In other news, insider Alan C.